Drug Profile
Betahistine - Obecure
Alternative Names: Histalean; OBE 101Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Obecure
- Class Amines; Anti-inflammatories; Antidementias; Pyridines; Small molecules; Vestibular disorder therapies
- Mechanism of Action Histamine H1 receptor agonists; Histamine H3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hyperlipidaemia; Obesity; Weight gain
Most Recent Events
- 31 Dec 2010 Obecure completes a phase I trial in healthy volunteers in Romania [NCT01168336]
- 26 Feb 2010 National Institutes of Health completes enrolment in its Phase-I trial (NCT00459992) for Obesity in USA
- 17 Feb 2010 Grunenthal and Obecure Pharmaceuticals enter into an extension of their original strategic supply agreement